Skip to content

Study · Animal study (in vivo) · mouse · 2023

1 result

Anti-VEGFR2 F(ab')2 drug conjugate promotes renal accumulation and glomerular repair in diabetic nephropathy.

Liu D, Song Y, Chen H, You Y, Zhu L, Zhang J, Xu X, Hu J, Huang X, Wu X, Xu X, Jiang S, Du Y

Nature communications13 Dec 2023Cited by 13 (Europe PMC)

PMID38092739 (opens in a new tab)PMCIDPMC10719340 (opens in a new tab)DOI10.1038/s41467-023-43847-2 (opens in a new tab)PepBankPUB-38092739
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Poor renal distribution of antibody-based drugs is the key factor contributing to low treatment efficiency for renal diseases and side effects. Here, we prepare F(ab')2 fragmented vascular endothelial growth factor receptor 2 antibody (anti-VEGFR2 (F(ab')2) to block VEGFR2 overactivation in diabetic nephropathy (DN). We find that the anti-VEGFR2 F(ab')2 has a higher accumulation in DN male mice kidneys than the intact VEGFR2 antibody, and simultaneously preserves the binding ability to VEGFR2. Furthermore, we develop an antibody fragment drug conjugate, anti-VEGFR2 F(ab')2-SS31, comprising the anti-VEGFR2 F(ab')2 fragment linked to the mitochondria-targeted antioxidant peptide SS31. We find that introduction of SS31 potentiates the efficacy of anti-VEGFR2 F(ab')2. These findings provide proof of concept for the premise that antibody fragment drug conjugate improves renal distribution and merits drug validation in renal disease therapy.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male mice with diabetic nephropathy, adding SS31 to the anti-VEGFR2 F(ab')2 fragment potentiated its efficacy.

    In plain wordsIn mice with diabetic kidney disease, adding SS31 to the antibody fragment made it work better than the fragment alone.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseEfficacy of anti-VEGFR2 F(ab')2 with versus without SS31
    Study

    mousen: not reported in source

    Diabetic nephropathy male mice
    Comparator
    Anti-VEGFR2 F(ab')2 without SS31
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We find that introduction of SS31 potentiates the efficacy of anti-VEGFR2 F(ab')2.
    2 context sentences
    Summary · context
    We find that the anti-VEGFR2 F(ab')2 has a higher accumulation in DN male mice kidneys than the intact VEGFR2 antibody, and simultaneously preserves the binding ability to VEGFR2.
    Summary · context
    Furthermore, we develop an antibody fragment drug conjugate, anti-VEGFR2 F(ab')2-SS31, comprising the anti-VEGFR2 F(ab')2 fragment linked to the mitochondria-targeted antioxidant peptide SS31.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.